Use of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing

Published: September 19, 2019

stem cells on a colorful background
  • Many lifesaving oncology drugs may adversely affect the cardiovascular (CV) system, causing irreversible cardiac injury and reduced quality of life.
  • The emergence of human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) as an in vitro research tool holds great promise for understanding drug-induced cardiotoxicity.
  • This statement reviews the challenges of cardio-oncology, strengths and limitations of using hiPSC-CMs to represent clinical findings in the non-clinical research space, and future directions for their further use.